Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy

BACKGROUND: Nilotinib inhibits the tyrosine kinase activities of ABL1/BCR-ABL1, KIT, and platelet-derived growth factor receptors (PDGFRs). The results of a phase III clinical trial indicated that nilotinib could not be recommended for broad use as first-line therapy for gastrointestinal stromal tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugase, Takahito, Takahashi, Tsuyoshi, Ishikawa, Takashi, Ichikawa, Hiroshi, Kanda, Tatsuo, Hirota, Seiichi, Nakajima, Kiyokazu, Tanaka, Koji, Miyazaki, Yasuhiro, Makino, Tomoki, Kurokawa, Yukinori, Yamasaki, Makoto, Takiguchi, Shuji, Wakai, Toshifumi, Mori, Masaki, Doki, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116018/
https://www.ncbi.nlm.nih.gov/pubmed/27864817
http://dx.doi.org/10.1186/s40792-016-0266-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116018/
https://www.ncbi.nlm.nih.gov/pubmed/27864817
http://dx.doi.org/10.1186/s40792-016-0266-y

Ejemplares similares